Anhui Provincial Cancer Hospital

Hefei 230088

4 studies enrolling now · 10 studies all time

What they study most

Breast Cancer, Gastric Cancer, Gastroesophageal Junction Cancer, HER2-positive Gastric Cancer, Head and Neck Cancer, Locally Advanced or Metastatic Unresectable Urothelial Cancer, Non-small Cell Lung Cancer, PD-L1 Negative, Relapsed or Refractory Peripheral T Cell Lymphoma, Solid Tumours, Triple Negative Breast Cancer

Studies at this site

• Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer — Recruiting now
• A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC) — Recruiting now
• Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations — Recruiting now
• Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer — Recruiting now
• Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread — Completed
• Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer — Running, not enrolling
• Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION) — Stopped early
• The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC — Completed
• Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer — Completed
• Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8) — Completed